Novartis partners with the Gates Foundation on one of the Holy Grails in gene therapy: a simple, in vivo approach to curing sickle cell disease
Having helped usher in a “new era” of sickle cell disease treatment with Adakveo, Novartis has set its sights on an even higher goal: a curative, relatively low cost, once-and-done in vivo gene therapy that can work in developing countries.
Tapping into the coffers of the Bill & Melinda Gates Foundation, the pharma giant says it will deploy its drug discovery and gene therapy experts in search of a product that can cater to regions with less resources. And they’re using today’s announcement to open its doors to any other groups that would like to pitch in.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
